Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.

You may also be interested in...

Roche Backs Out Of Daclizumab Transplantation Deal With PDL

PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.

PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals

The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.

PDL’s Terlipressin Fails Phase III Trial; Company To Meet With FDA

Late-stage development compound was evaluated for treatment of type 1 hepatorenal syndrome.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts